Staphylococcus Aureus Clinical Trial
— SALTOfficial title:
Staphylococcus Aureus Surgical Site Infection Multinational Epidemiology in Europe
NCT number | NCT03353532 |
Other study ID # | SALT |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | August 1, 2017 |
Est. completion date | January 31, 2021 |
Verified date | May 2021 |
Source | University of Cologne |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This is a retrospective multinational, multicenter cohort study with a nested case-control. The study includes all surgical procedures performed at a participating site to prevent bias. Data will be assessed in two populations. Cohort population: Export of electronic file data on demographics, surgical procedure ICPM code, duration of procedure, American Society of Anesthesiologists (ASA) score, body mass index, comorbidity ICD codes, and wound class of all patients undergoing surgery. Nested case-control population: For patients establishing S. aureus SSI and 1:1 matched controls from the same center further data will be captured: Length of hospitalization, length of ICU stay and reason as well as attribution to SSI, survival at 30 and at 90 days, antibiotic treatments including duration, functional status at admission and at final discharge; necessity for surgical revision, and death attributed to SSI. If readmission is necessary, reason and attribution to SSI, length of hospitalization and length of ICU stay as well as all antibiotic treatments and their duration will be recorded. The cases causative pathogens including resistance patterns and type of SSI according to CDC criteria will be captured. Matching criteria comprise the following: - Type of procedure - Age - ASA score - BMI - Duration of procedure (as percentile for this procedure) - Diabetes - Sex
Status | Completed |
Enrollment | 178902 |
Est. completion date | January 31, 2021 |
Est. primary completion date | January 1, 2021 |
Accepts healthy volunteers | |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age =18 years at the time of surgery Exclusion Criteria: - Cases with missing data defined as "missing completely at random" (MCAR) - Infection at the time of surgery |
Country | Name | City | State |
---|---|---|---|
France | Centre Hospitalier Départemental Vendee | La Roche-sur-Yon | |
France | Centre Hospitalier et Universitaire de Limoges | Limoges | |
France | Centre Hospitalier Régional et Universitaire de Tours | Tours | |
Germany | University Hospital Bonn | Bonn | |
Germany | University Hospital Cologne | Cologne | NRW |
Germany | Jena University Hospital | Jena | |
Germany | Hospital of the University of Munich | Munich | |
Italy | University of Udine and Azienda Sanitaria Universitaria Integrata | Udine | |
Spain | Hospital Clínic Barcelona | Barcelona | |
Spain | Institut Hospital del Mar d'Investigacions Mèdiques | Barcelona | |
Spain | Hospital General Universitario Gregorio Marañón e Instituto de Investigación Sanitaria Gregorio Marañón | Madrid | |
Spain | Hospital Universitario Ramón y Cajal | Madrid | |
Spain | Hospital Universitari i Politècnic La Fe | Valencia | |
United Kingdom | Manchester University NHS Foundation Trust (MFT) | Manchester |
Lead Sponsor | Collaborator |
---|---|
University of Cologne | Pfizer |
France, Germany, Italy, Spain, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | To characterize the composition of the surgical patient population in Europe | The composition of the surgical patient population in Europe will be performed by subgroup Analysis of the cohort | 30 days from surgical procedure | |
Other | To estimate the number of patients at risk for Staphylococcus aureus surgical site infection | This will be extrapolated from epidemiologcal data assessed within the cohort | 30 days from surgical procedure | |
Other | To estimate the economic burden, including direct treatment and indirect costs, imposed by Staphylococcus aureus surgical site infections in Europe | Direct and indirect Treatment costs will be assessed within the case-control part. Cases and controls will be compared regarding costs. | 30 days from surgical procedure | |
Primary | To determine overall incidence of Staphylococcus aureus surgical site infections in Europe | Surgical site infections will be determined within the cohort of all patients that underwent surgery within 1 year at all participating sites. | 30 days from surgical procedure | |
Primary | To determine procedure specific incidence of Staphylococcus aureus surgical site infections in Europe | Surgical site infections will be determined within the cohort of all patients that underwent surgery within 1 year at all participating sites. A subgroup Analysis will reveal procedure specific incidence. | 30 days from surgical procedure | |
Secondary | To determine the overall outcomes of Staphylococcus aureus surgical site infections in Europe | The Outcome will be assessed within the case-control part and achieved by comparison of Overall Outcome of cases and controls | 30 days from surgical procedure | |
Secondary | To determine the procedure specific outcomes of Staphylococcus aureus surgical site infections in Europe | The Outcome will be assessed within the case-control part and achieved by comparison of procedure specific Outcome of cases and controls | 30 days from surgical procedure | |
Secondary | To determine the overall economic burden of Staphylococcus aureus surgical site infections in Europe | The economic burden will be assessed within the case-control part and achieved by comparison of Overall economic burden (i.e. ICU Treatment, hemodialysis and mechanical Ventilation) of cases and controls | 30 days from surgical procedure | |
Secondary | To determine the procedure specific economic burden of Staphylococcus aureus surgical site infections in Europe | The economic burden will be assessed within the case-control part and achieved by comparison of procedure specific economic burden (i.e. ICU Treatment, hemodialysis and mechanical Ventilation) of cases and controls | 30 days from surgical procedure |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05073926 -
Rifampicin Resistance in S. Aureus During and After Treatment for Latent Tuberculosis
|
||
Completed |
NCT01212120 -
The Foot in Your Nose Study: Links Between Nasal Staphylococcus Aureus Colonies and Diabetic Foot Lesion Infections
|
N/A | |
Completed |
NCT00801879 -
Mupirocin Ointment to Eliminate Nasal Carriage of Staphylococcus Aureus in HIV Infection
|
Phase 4 | |
Terminated |
NCT03638947 -
Reducing Perioperative S. Aureus Transmission
|
N/A | |
Recruiting |
NCT05331885 -
A Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin in Mechanically Ventilated Adult Subjects - 2
|
Phase 3 | |
Recruiting |
NCT05094570 -
Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP
|
Phase 4 | |
Not yet recruiting |
NCT05092464 -
Exploratory Study to Evaluate the Application of NLAC Cream in Adults With Atopic Dermatitis
|
N/A | |
Recruiting |
NCT05695196 -
Feasibility and Safety Study of Parent-to-Child Nasal Microbiota Transplant
|
Phase 1 | |
Enrolling by invitation |
NCT04666532 -
S. Aureus Translocation From Skin and Nose to Periprosthetic Tissues
|
||
Active, not recruiting |
NCT02572791 -
Staph Household Intervention for Eradication (SHINE)
|
Phase 4 | |
Recruiting |
NCT04274348 -
Staphylococcal Toxins in Atopic Dermatitis and Eczema Herpeticum
|
N/A | |
Enrolling by invitation |
NCT05880069 -
Clinical Outcomes in Patients With Infection by Resistant Microorganism
|
||
Completed |
NCT01011335 -
Staphylococcus Aureus Toxoids Phase 1-2 Vaccine Trial
|
Phase 1/Phase 2 | |
Completed |
NCT03816956 -
Adjunctive Therapy to Antibiotics in the Treatment of S. Aureus Ventilator-Associated Pneumonia With AR-301
|
Phase 3 | |
Not yet recruiting |
NCT04884958 -
A Study to Investigate the Transmission and Burden of PVL-MRSA in Households in Sri Lanka
|
||
Completed |
NCT01105767 -
Methicillin-resistant Staphylococcus Aureus (MRSA) Skin and Soft Tissue Infection (SSTI) Prevention in Military Trainees
|
N/A | |
Completed |
NCT00475930 -
Chlorhexidine Impregnated Cloths to Prevent Skin and Soft Tissue Infections in Marine Officer Candidates
|
N/A | |
Completed |
NCT00507247 -
Daptomycin in the Treatment of Catheter-Related Staphylococcus Aureus
|
Phase 2 | |
Recruiting |
NCT03220386 -
Methicillin-sensitive and Methicillin-resistant Staphylococcus Aureus (MSSA/MRSA) - Point-of-care-testing (POCT) in Clinical Decision Making
|
N/A | |
Completed |
NCT03140423 -
Mupirocin-Iodophor ICU Decolonization Swap Out Trial
|
Phase 4 |